2018
Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)
Beach T, Serrano G, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé A, Letournel F, Munoz D, White C, Schneider J, Crary J, Sue L, Adler C, Glass M, Intorcia A, Walker J, Foroud T, Coffey C, Ecklund D, Riss H, Goßmann J, König F, Kopil C, Arnedo V, Riley L, Linder C, Dave K, Jennings D, Seibyl J, Mollenhauer B, Chahine L, Guilmette L, Russell D, Noyes-Lloyd C, Mitchell C, Smith D, Potter M, Case R, Lott D, Duffy A, Hogarth P, Cresswell M, Akhtar R, Purri R, Amara A, Blair C, Keshavarzian A, Marras C, Visanji N, Rothberg B, Oza V. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). Journal Of Neuropathology & Experimental Neurology 2018, 77: 793-802. PMID: 30107604, PMCID: PMC6097838, DOI: 10.1093/jnen/nly056.Peer-Reviewed Original ResearchConceptsParkinson's diseaseASyn pathologyΑ-synuclein pathologySubmandibular gland biopsyPeripheral biopsiesControl subjectsGland biopsyBlinded panelImmunohistochemical methodsImmunoperoxidase methodMonoclonal antibodiesScore agreementNeuropathologistsPathologyBiopsySkinSubsequent testingSampling study
2014
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
Beal M, Oakes D, Shoulson I, Henchcliffe C, Galpern W, Haas R, Juncos J, Nutt J, Voss T, Ravina B, Shults C, Helles K, Snively V, Lew M, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters C, Figueroa A, Arkun A, Brodsky M, Ondo W, Hunter C, Jimenez-Shahed J, Palao A, Miyasaki J, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell D, Cotto C, Friedman J, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford D, Grimes D, Cote D, Conway J, Siderowf A, Evatt M, Sommerfeld B, Lieberman A, Okun M, Rodriguez R, Merritt S, Swartz C, Martin W, King P, Stover N, Guthrie S, Watts R, Ahmed A, Fernandez H, Winters A, Mari Z, Dawson T, Dunlop B, Feigin A, Shannon B, Nirenberg M, Ogg M, Ellias S, Thomas C, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser R, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi K, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson V, Markind S, Pelikan M, Perlmutter J, Hartlein J, Molho E, Evans S, Adler C, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey M, Hermanowicz N, Niswonger S, Shill H, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer K, Bergholte J, Propsom C, Stacy M, Field J, Mihaila D, Chilton M, Uc E, Sieren J, Simon D, Kraics L, Silver A, Boyd J, Hamill R, Ingvoldstad C, Young J, Thomas K, Kostyk S, Wojcieszek J, Pfeiffer R, Panisset M, Beland M, Reich S, Cines M, Zappala N, Rivest J, Zweig R, Lumina L, Hilliard C, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang U, Young J, Rao J, Cook M, Severt L, Boyar K. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurology 2014, 71: 543-552. PMID: 24664227, DOI: 10.1001/jamaneurol.2014.131.Peer-Reviewed Original ResearchConceptsTotal UPDRS scoresUPDRS scoresCoenzyme Q10PD medicationsFinal visitClinical benefitClinical trialsEarly-phase human studiesPrevious phase II studyDouble-blind clinical trialMini-Mental State Examination scoreParticipants 30 yearsPhase III randomizedPrespecified futility criterionDrug-induced parkinsonismPhase II studyActive treatment groupIU/dEarly Parkinson's diseaseHistory of strokePossible clinical benefitPrimary outcome measureState Examination scoreParkinson's disease modelDiagnosis of PD
2013
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Kang J, Irwin D, Chen-Plotkin A, Siderowf A, Caspell C, Coffey C, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner C, Singleton A, Toga A, Chowdhury S, Mollenhauer B, Trojanowski J, Shaw L, Lasch S, Flagg E, Poewe W, Sherer T, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Uribe L, Yankey J, Crawford K, Scutti A, Casalin P, Malferrari G, Hawkins K, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Jankovic J, Hunter C, Stern M, Darin A, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Oertel W, Willeke D, Shill H, Fernandez H, Mule J, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, McCoy A, Brooks D, Shah B, Barone P, Isaacson S, James A, Espay A, Espay K, Rowe D, Ranola M. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology 2013, 70: 1277-1287. PMID: 23979011, PMCID: PMC4034348, DOI: 10.1001/jamaneurol.2013.3861.Peer-Reviewed Original ResearchConceptsDrug-naive patientsEarly Parkinson's diseaseCSF biomarkersΒ-amyloid 1CSF Aβ1-42P-tau181Parkinson's diseaseT-tauAβ1-42Healthy controlsΑ-synucleinClinical featuresPPMI cohortParkinson's Progression Markers Initiative (PPMI) studyLower CSF Aβ1-42Early-stage Parkinson's diseaseT-tau/Aβ1Lower Aβ1-42P-tau181 concentrationsCSF t-tauΑ-synuclein levelsCerebrospinal fluid levelsCross-sectional studyEnzyme-linked immunosorbent assaySignificant correlation